These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11435303)

  • 21. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12 --> VAL fibrinogen variant.
    Mathonnet F; Peltier JY; Detruit H; de Raucourt E; Alvarez JC; Mazmanian GM; de Mazancourt P
    Blood Coagul Fibrinolysis; 2002 Mar; 13(2):149-53. PubMed ID: 11914657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275 Arg-->Cys substitution.
    Steinmann C; Bögli C; Jungo M; Lämmle B; Heinemann G; Wermuth B; Redaelli R; Baudo F; Furlan M
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):463-71. PubMed ID: 7841300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
    Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
    Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'.
    Okumura N; Terasawa F; Haneishi A; Fujihara N; Hirota-Kawadobora M; Yamauchi K; Ota H; Lord ST
    J Thromb Haemost; 2007 Dec; 5(12):2352-9. PubMed ID: 17922804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normal plasmic cleavage of the gamma-chain variant of "fibrinogen Saga" with an Arg-275 to His substitution.
    Yamazumi K; Terukina S; Onohara S; Matsuda M
    Thromb Haemost; 1988 Dec; 60(3):476-80. PubMed ID: 2976995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene.
    Liu CY; Koehn JA; Morgan FJ
    J Biol Chem; 1985 Apr; 260(7):4390-6. PubMed ID: 3156856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His.
    Luo M; Deng D; Xiang L; Cheng P; Liao L; Deng X; Yan J; Lin F
    Medicine (Baltimore); 2016 Sep; 95(39):e4864. PubMed ID: 27684817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp).
    Brennan SO; Hammonds B; George PM
    J Clin Invest; 1995 Dec; 96(6):2854-8. PubMed ID: 8675656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
    Vila V; Regañón E; Aznar J; Navarro G; Salas M
    Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitution of gamma Arg-275 by Cys in an abnormal fibrinogen, "fibrinogen Osaka II". Evidence for a unique solitary cystine structure at the mutation site.
    Terukina S; Matsuda M; Hirata H; Takeda Y; Miyata T; Takao T; Shimonishi Y
    J Biol Chem; 1988 Sep; 263(27):13579-87. PubMed ID: 2971042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.
    Flood VH; Al-Mondhiry HA; Farrell DH
    Br J Haematol; 2006 Jul; 134(2):220-6. PubMed ID: 16846481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinogen Chapel Hill II: defective in reactions with thrombin, factor XIIIa and plasmin.
    Carrell N; McDonagh J
    Br J Haematol; 1982 Sep; 52(1):35-47. PubMed ID: 6126210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III.
    Furlan M; Steinmann C; Jungo M; Bögli C; Baudo F; Redaelli R; Fedeli F; Lämmle B
    J Biol Chem; 1994 Dec; 269(52):33129-34. PubMed ID: 7806542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization.
    Homer VM; Mullin JL; Brennan SO; Barr A; George PM
    J Thromb Haemost; 2003 Jun; 1(6):1245-50. PubMed ID: 12871326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
    Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization.
    Terukina S; Yamazumi K; Okamoto K; Yamashita H; Ito Y; Matsuda M
    Blood; 1989 Dec; 74(8):2681-7. PubMed ID: 2819242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinogen Baltimore I: polymerization defect associated with a gamma 292Gly----Val (GGC----GTC) mutation.
    Bantia S; Mane SM; Bell WR; Dang CV
    Blood; 1990 Dec; 76(11):2279-83. PubMed ID: 2257302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
    Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
    Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.